ArticleFrontiers in neurology2022

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.

Robert A Hauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.